Bronwyn A. L. Crawford
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bronwyn A. L. Crawford has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Geoffrey William McCaughan
Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia
2 shared publications A. J. Donaghy
Royal Prince Alfred Hospital and University of Sydney
1 shared publicationC. Kam
Royal Prince Alfred Hospital and University of Sydney
1 shared publicationChanna Perera
Orange Base Hospital, Orange
1 shared publicationDavid J. Handelsman
1 shared publicationEternity D Labio
ED Labio is a Clinical Associate Professor in Gastroenterology, Department of Medicine, University of the Philippines, Philippine General Hospital, Manila, Philippines
1 shared publication
Latest Publications
- 1 October 2007
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 32 (10) , 790-792
Bone Scintigraphy in Acute Intraosseous Disc Herniation
A 57-year-old woman initially presented with the acute onset of low back pain after gardening. Plain film at that time was reported as showing Scheurmann's disease of the lumbar spine. The pain resolved slowly, but recurred acutely after minimal trauma 5 months later. Bone scintigraphy revealed increased uptake in L4 and L5 around the disc space, thought to be suspicious for discitis. Other blood tests revealed a high alkaline phosphatase level with an elevated bone component. The erythrocyte sedimentation rate and leukocyte count were not elevated. Magnetic resonance imaging (MRI) showed an acute disc herniation of the L4/L5 disc into the lower body of L4 with considerable bone marrow edema. Follow-up imaging showed substantial resolution of marrow edema 18 months later. Acute disc herniation has rarely been reported in the scintigraphic literature and should be kept in mind in such circumstances, particularly in older patients.
- 1 October 2007
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 32 (10) , 790-792
Bone Scintigraphy in Acute Intraosseous Disc Herniation
A 57-year-old woman initially presented with the acute onset of low back pain after gardening. Plain film at that time was reported as showing Scheurmann's disease of the lumbar spine. The pain resolved slowly, but recurred acutely after minimal trauma 5 months later. Bone scintigraphy revealed increased uptake in L4 and L5 around the disc space, thought to be suspicious for discitis. Other blood tests revealed a high alkaline phosphatase level with an elevated bone component. The erythrocyte sedimentation rate and leukocyte count were not elevated. Magnetic resonance imaging (MRI) showed an acute disc herniation of the L4/L5 disc into the lower body of L4 with considerable bone marrow edema. Follow-up imaging showed substantial resolution of marrow edema 18 months later. Acute disc herniation has rarely been reported in the scintigraphic literature and should be kept in mind in such circumstances, particularly in older patients.
- 1 December 2006
- Published by Springer Nature in Nature Clinical Practice Gastroenterology & Hepatology
- Vol. 3 (12) , 689-699
Vitamin D replacement for cirrhosis-related bone disease
The osteoporotic fracture rate in patients with chronic liver disease is approximately twice that of age-matched, control individuals. About 66% of patients with moderately severe cirrhosis and 96% of patients awaiting liver transplantation have vitamin D deficiency. Studies have shown a strong correlation between vitamin D deficiency and bone density, particularly in the hip. Previous studies of vitamin D therapy in cirrhosis-related bone disease have had major design flaws. Most reports and guidelines on the treatment of hepatic bone disease have concluded that vitamin D deficiency does not have a significant pathogenetic role in the development of osteoporosis in cirrhosis, and that there is no evidence for a therapeutic effect of vitamin D supplementation. Conversely, it is generally recommended that patients with cirrhosis and low bone density should receive calcium and vitamin D supplementation; yet there is a paucity of reliable data on the optimal doses to use, as well as a lack of clearly demonstrated benefit. We believe that clinical trials of vitamin D therapy in these patients with liver disease are warranted. As low-dose oral supplementation often will not normalize vitamin D levels or suppress parathyroid hormone activity in cirrhotic patients, high-dose, parenteral vitamin D might be preferable, but further long-term studies are required to assess the benefits and safety of this approach.
- 1 December 2006
- Published by Springer Nature in Nature Clinical Practice Gastroenterology & Hepatology
- Vol. 3 (12) , 689-699
Vitamin D replacement for cirrhosis-related bone disease
The osteoporotic fracture rate in patients with chronic liver disease is approximately twice that of age-matched, control individuals. About 66% of patients with moderately severe cirrhosis and 96% of patients awaiting liver transplantation have vitamin D deficiency. Studies have shown a strong correlation between vitamin D deficiency and bone density, particularly in the hip. Previous studies of vitamin D therapy in cirrhosis-related bone disease have had major design flaws. Most reports and guidelines on the treatment of hepatic bone disease have concluded that vitamin D deficiency does not have a significant pathogenetic role in the development of osteoporosis in cirrhosis, and that there is no evidence for a therapeutic effect of vitamin D supplementation. Conversely, it is generally recommended that patients with cirrhosis and low bone density should receive calcium and vitamin D supplementation; yet there is a paucity of reliable data on the optimal doses to use, as well as a lack of clearly demonstrated benefit. We believe that clinical trials of vitamin D therapy in these patients with liver disease are warranted. As low-dose oral supplementation often will not normalize vitamin D levels or suppress parathyroid hormone activity in cirrhotic patients, high-dose, parenteral vitamin D might be preferable, but further long-term studies are required to assess the benefits and safety of this approach.
- 17 May 2004
- Published by AMPCo in Medical Journal of Australia
- Vol. 180 (10) , 540-541
Octreotide treatment for sulfonylurea‐induced hypoglycaemia
Click on the article title to read more.
- 17 May 2004
- Published by AMPCo in Medical Journal of Australia
- Vol. 180 (10) , 540-541
Octreotide treatment for sulfonylurea‐induced hypoglycaemia
Click on the article title to read more.
- 19 September 2003
- Published by Springer Nature in Osteoporosis International
- Vol. 14 (12) , 987-994
The heterogeneity of bone disease in cirrhosis: a multivariate analysis
This study aimed to assess the clinical, biochemical and hormonal factors contributing to low bone density in a large ambulatory group of patients with cirrhosis of diverse aetiology. Bone density of the lumbar spine, neck of femur, total hip, total body, as well as total body fat, was measured by dual X-ray (DEXA) absorptiometry in 81 men and 32 women (average age 50.3 years). Morning blood and urine samples were taken for hormonal and biochemical analysis. Viral hepatitis was the most common cause of cirrhosis (54%) and the severity of cirrhosis ranged from Child-Pugh A5–C14. Osteoporosis was most common in the lumbar spine but was present at any site in 31% of women and 22% of men, with osteopenia present in another 40% of both genders. Urinary deoxypyridinoline, a marker of bone resorption, was elevated in 56% of patients and was associated with increasing severity of cirrhosis and a higher prevalence of osteoporosis, particularly of the lumbar spine. Hip-bone density was primarily affected by low 25-hydroxyvitamin D levels and was associated with secondary hyperparathyroidism in one third of these patients. Additional important predictors for low bone density at all sites were age in women and testosterone in men. These findings indicate that, although the pathophysiology of osteoporosis in chronic liver disease is heterogeneous, high bone turnover may be the underlying pathophysiological mechanism in a significant subgroup of cirrhotic patients and may reflect metabolic effects of hypogonadism or secondary hyperparathyroidism on bone.
- 19 September 2003
- Published by Springer Nature in Osteoporosis International
- Vol. 14 (12) , 987-994
The heterogeneity of bone disease in cirrhosis: a multivariate analysis
This study aimed to assess the clinical, biochemical and hormonal factors contributing to low bone density in a large ambulatory group of patients with cirrhosis of diverse aetiology. Bone density of the lumbar spine, neck of femur, total hip, total body, as well as total body fat, was measured by dual X-ray (DEXA) absorptiometry in 81 men and 32 women (average age 50.3 years). Morning blood and urine samples were taken for hormonal and biochemical analysis. Viral hepatitis was the most common cause of cirrhosis (54%) and the severity of cirrhosis ranged from Child-Pugh A5–C14. Osteoporosis was most common in the lumbar spine but was present at any site in 31% of women and 22% of men, with osteopenia present in another 40% of both genders. Urinary deoxypyridinoline, a marker of bone resorption, was elevated in 56% of patients and was associated with increasing severity of cirrhosis and a higher prevalence of osteoporosis, particularly of the lumbar spine. Hip-bone density was primarily affected by low 25-hydroxyvitamin D levels and was associated with secondary hyperparathyroidism in one third of these patients. Additional important predictors for low bone density at all sites were age in women and testosterone in men. These findings indicate that, although the pathophysiology of osteoporosis in chronic liver disease is heterogeneous, high bone turnover may be the underlying pathophysiological mechanism in a significant subgroup of cirrhotic patients and may reflect metabolic effects of hypogonadism or secondary hyperparathyroidism on bone.
- 1 July 2003
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 88 (7) , 3167-3176
Randomized Placebo-Controlled Trial of Androgen Effects on Muscle and Bone in Men Requiring Long-Term Systemic Glucocorticoid Treatment
Long-term glucocorticoid therapy in men is associated with loss of bone and muscle mass as well as a decrease in serum testosterone. We tested the effect of two androgens, testosterone and its minimally aromatizable analog nandrolone, on muscle mass (dual x-ray absorptiometry), muscle strength (knee flexion and extension by isokinetic dynamometry), bone mineral density (BMD), and quality of life (Qualeffo-41 questionnaire) in 51 men on a mean daily prednisone dose of 12.6 +/- 2.2 mg. Men were randomized, double blind, to testosterone (200 mg mixed esters), nandrolone decanoate (200 mg), or placebo given every fortnight by im injection for 12 months. At 12 months, both androgens increased muscle mass (mean change from baseline +3.5%, +5.8%, and -0.9% in testosterone, nandrolone, and placebo groups, respectively, P < 0.0001) and muscle strength (P < 0.05). Lumbar spine BMD increased significantly only in men treated with testosterone (4.7 +/- 1.1%, P < 0.01). There was no significant change in hip or total body BMD. Testosterone, but not nandrolone or placebo, improved overall quality of life (P < 0.001). These results suggest that androgen therapy may have a role in ameliorating adverse effects of glucocorticoid therapy such as muscle and bone loss and aromatization is necessary for androgen action on bone but not on muscle.
- 1 July 2003
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 88 (7) , 3167-3176
Randomized Placebo-Controlled Trial of Androgen Effects on Muscle and Bone in Men Requiring Long-Term Systemic Glucocorticoid Treatment
Long-term glucocorticoid therapy in men is associated with loss of bone and muscle mass as well as a decrease in serum testosterone. We tested the effect of two androgens, testosterone and its minimally aromatizable analog nandrolone, on muscle mass (dual x-ray absorptiometry), muscle strength (knee flexion and extension by isokinetic dynamometry), bone mineral density (BMD), and quality of life (Qualeffo-41 questionnaire) in 51 men on a mean daily prednisone dose of 12.6 +/- 2.2 mg. Men were randomized, double blind, to testosterone (200 mg mixed esters), nandrolone decanoate (200 mg), or placebo given every fortnight by im injection for 12 months. At 12 months, both androgens increased muscle mass (mean change from baseline +3.5%, +5.8%, and -0.9% in testosterone, nandrolone, and placebo groups, respectively, P < 0.0001) and muscle strength (P < 0.05). Lumbar spine BMD increased significantly only in men treated with testosterone (4.7 +/- 1.1%, P < 0.01). There was no significant change in hip or total body BMD. Testosterone, but not nandrolone or placebo, improved overall quality of life (P < 0.001). These results suggest that androgen therapy may have a role in ameliorating adverse effects of glucocorticoid therapy such as muscle and bone loss and aromatization is necessary for androgen action on bone but not on muscle.